|
28 Nov 2018 |
Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy
|
|
27 Nov 2018 |
Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome
|
|
27 Nov 2018 |
Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for Inflammatory Bowel Disease
|
|
27 Nov 2018 |
DNAtrix's Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial
|
|
27 Nov 2018 |
Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis
|
|
27 Nov 2018 |
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
|
|
26 Nov 2018 |
Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer
|
|
26 Nov 2018 |
Inovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb™) Platform In Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019
|
|
23 Nov 2018 |
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
|
|
21 Nov 2018 |
Kolon TissueGene Doses First Patient in US Phase III Clinical Trial
|
|
21 Nov 2018 |
Eureka Therapeutics Announces Publication of Preclinical Study Validating its ARTEMIS Platform Designed to Mitigate the Risk of Cytokine Release Syndrome (CRS) and Neurotoxicity
|
|
19 Nov 2018 |
Rocket Pharmaceuticals Announces Clearance of IND for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I)
|
|
19 Nov 2018 |
BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis
|
|
19 Nov 2018 |
Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
|
|
19 Nov 2018 |
Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
|
|
16 Nov 2018 |
Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study
|
|
16 Nov 2018 |
uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
|
|
14 Nov 2018 |
Virion Biotherapeutics Demonstrates Preclinical Proof-of-Concept for First Therapeutic Interfering Particle Candidate in Respiratory Virus Infections
|
|
13 Nov 2018 |
Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting
|
|
13 Nov 2018 |
Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500
|
|
13 Nov 2018 |
Ophthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration
|
|
13 Nov 2018 |
New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation
|
|
13 Nov 2018 |
Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer
|
|
13 Nov 2018 |
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions
|
|
13 Nov 2018 |
MolMed and Dompé announce the mutual termination of the license and distribution agreement for Zalmoxis®.
|
